Pallas health research and consultancy

What Pallas health research and consultancy does

P95 is a privately held, full-service Contract Research Organization (CRO) headquartered in Leuven, Belgium, specializing in vaccine development and infectious disease clinical research. Founded in 1998, the company delivers end-to-end Phase I-IV clinical trials, epidemiology and real-world evidence (RWE) studies, and supporting data management, biostatistics, pharmacovigilance, and medical writing services to pharmaceutical and biotechnology firms, vaccine developers, and global health organizations. The company has incorporated two legacy brands into its platform: Assign DMB (an Austrian CRO focused on data management and biostatistics) and 4Clinics (a CRO specializing in vaccines and immunotherapeutics).

The operating model is built around four integrated service lines: Clinical Trial Delivery, Epidemiology and RWE Solutions, an Africa and LMICs regional specialization, and Data, Analysis, Safety and Writing. With approximately 500 staff and an operational footprint across 40 countries on five continents (regional hubs in Africa, Latin America, North America, and Southeast Asia), P95 reports having delivered 1,000+ Phase I-IV clinical trials and 400+ RWE projects over more than 25 years. Therapeutic focus is concentrated in vaccines and infectious diseases, with adjacent coverage in neuroscience (CNS) and cardio-metabolic/renal diseases.

P95 generates revenue through professional services on a custom, quote-based, project-by-project basis, with multi-year contracts and a sales-led go-to-market motion that relies on direct enterprise engagement, proposal requests, and account management teams targeting pharma, biotech, vaccine developers, and global health institutions. Marketing is executed through content (website, publications, case studies), LinkedIn, webinars, a podcast, industry events, and a newsletter. Ownership is private with no disclosed parent company, investors, or cap-table information, and no public revenue or funding data is available.

Name

Pallas health research and consultancy

Legal name

P95

Website

https://pallas-healthresearch.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

P95 is a Belgium-headquartered, full-service CRO specializing in vaccines, infectious diseases, CNS, and cardio-metabolic/renal clinical research. With ~500 staff across 40 countries, it delivers Phase I-IV trials, epidemiology and RWE studies, and data/biostatistics services to pharma, biotech, vaccine developers, and global health organizations.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Clinical trial services
• Contract research organization
• Vaccine development research
• Epidemiology studies
• Real-world evidence

Headquarters

HQ city

Rotterdam

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO providing clinical trial support services including trial delivery, epidemiology, data management, biostatistics, safety management, and medical writing on a project-by-project basis for pharmaceutical, biotech, and global health organizations.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

P95 is a full-service Contract Research Organization (CRO) that provides end-to-end clinical trial solutions and epidemiological research services for vaccines and infectious diseases. Offerings span Phase I-IV clinical trial delivery, non-interventional studies and real-world evidence generation, data management, biostatistics, pharmacovigilance, and medical writing. The firm also runs specialized regional research operations in Africa and low-to-middle-income countries (LMICs), serving pharmaceutical companies, biotech firms, vaccine developers, and global health organizations.

Product overview

P95 is a full-service Contract Research Organization (CRO) specializing in vaccine development and infectious diseases. The company operates as a platform of integrated service offerings including Clinical Trial Delivery, Epidemiology and Real-World Evidence Solutions, Africa and LMICs regional specialization, and Data, Analysis, Safety and Writing services. These services are designed to work together to provide end-to-end support from Phase I-IV clinical trials to epidemiological research and non-interventional studies, covering study design, site identification, trial management, safety management, data analysis, and medical writing. With 500 staff and over 25 years of collective experience, P95 combines clinical excellence with real-world evidence expertise and regional focus to advance vaccine development and deliver impactful treatment outcomes worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Delivery

Quantifiable outcome

• 1000+ clinical trials Phase I-IV completed
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Assign DMBcoreOthersAustrian CRO founded in 2005, acquired and integrated into P95. Continues expertise in data management and biostatistics as part of P95's service offerings.
• 4ClinicscoreOthersCRO founded in 1997 with expertise in vaccines and immunotherapeutics. Capabilities continue today within P95 following legacy integration.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pharm-Olam: Pharm-Olam is a mid-size global CRO with explicit focus on vaccines, infectious diseases, and oncology. It directly competes with P95 for the same vaccine-focused Phase I-IV trial and epidemiology contracts from pharma, biotech, and government sponsors.
• The Emmes Company: Emmes is a mid-size CRO specialized in vaccines, infectious diseases, and public health research, with strong government and global health organization client base. It is highly comparable to P95 in therapeutic focus, customer mix, and full-service CRO model.
• Julius Clinical: Julius Clinical is a Netherlands-based CRO with therapeutic expertise in central nervous system diseases and cardio-metabolic disorders — therapeutic areas explicitly listed under P95's expertise. It is a directly comparable mid-size specialized CRO partner/competitor.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size global CRO focused on complex clinical trials in specialty therapeutic areas. It competes directly with P95 for vaccine and infectious disease trial work from mid-size pharma and biotech clients.

Broad incumbents

• ICON plc: ICON plc is a top-tier global CRO providing full-service clinical development, including vaccine and infectious disease programs, alongside commercial and consulting services. Comparable to P95 as a full-service competitor with significantly larger scale and broader therapeutic coverage.
• Medpace: Medpace is a mid-to-large full-service CRO with strong therapeutic expertise across multiple disease areas. It overlaps with P95 on vaccine and infectious disease trial execution and competes for similar mid-size pharma and biotech sponsor contracts.
• IQVIA: IQVIA is the largest global CRO and life sciences technology vendor, offering full-service clinical trial delivery, real-world evidence, and epidemiology across all therapeutic areas. It competes with P95 for vaccine and infectious disease trial contracts but at significantly greater scale and broader scope.
• Syneos Health: Syneos Health is a large global biopharmaceutical solutions organization offering full-service CRO capabilities including clinical development across vaccines and infectious diseases. It is a scaled competitor to P95 in the same clinical trial delivery market.
• Parexel International: Parexel is a major global full-service CRO with deep vaccine and infectious disease capabilities. It competes with P95 across Phase I-IV trials, biostatistics, pharmacovigilance, and regulatory services but operates at materially greater scale and therapeutic breadth.

Regional players

• Novotech: Novotech is a leading Asia-Pacific-headquartered CRO with growing global presence, focused on biotech clinical development across multiple therapeutic areas including infectious diseases. It is comparable to P95 as a mid-size full-service CRO targeting biotech and pharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pallas-health-research-and-consultancy
• Xx.com/PallasHrc
• Facebookfacebook.com/Pallas-Health-research-and-consultancy-100067101547554

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pallas health research and consultancy